The EFNA1 Knockout HeLa Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, designed for loss?of?function studies of the EFNA1 gene. This polyclonal pool provides a heterogeneous collection of cells carrying targeted gene disruptions, enabling robust phenotypic analysis without clonal selection artifacts. The knockout model serves as a versatile tool for investigating ephrin?A1?dependent signaling in cervical cancer biology.
The parental HeLa cell line is a well?characterized human cervical epithelial adenocarcinoma cell line originally established from the tumor of Henrietta Lacks. These cells harbor human papillomavirus type 18 (HPV?18) sequences and exhibit an aneuploid karyotype. HeLa cells are widely employed as a model for cervical cancer and epithelial cell biology, offering easy culture and reproducible experimental conditions for studying oncogenic signaling, cytoskeletal dynamics, and cell migration.
EFNA1 encodes ephrin?A1, a glycosylphosphatidylinositol (GPI)?anchored ligand that primarily binds EphA receptor tyrosine kinases, notably EphA2. Ephrin?A1/EphA interactions trigger bidirectional signaling: forward signaling through EphA receptors activates Src kinase, focal adhesion kinase (FAK), and downstream effectors such as RhoA, Rac1, ERK1/2, and Akt, while reverse signaling modulates integrin function and actin remodeling. Upstream regulators include hypoxia?inducible factor 1?alpha (HIF1A), tumor necrosis factor?alpha (TNF???), transforming growth factor?beta (TGF???), and p53. EFNA1 knockout abrogates these signaling cascades, impairing cell?cell repulsion, adhesion turnover, and directional migration.
In the HeLa cervical cancer context, EFNA1 knockout represents a powerful model to dissect the role of ephrin?A1 in tumor cell motility and invasion. Overexpression of EFNA1 has been associated with aggressive phenotypes in cervical, lung, and breast cancers, partly through enhanced EphA2?driven angiogenic signaling and FAK?RhoA?mediated cytoskeletal reorganization. Disruption of EFNA1 in HeLa cells allows researchers to directly test how loss of ephrin?A1 impacts these oncogenic processes, as well as crosstalk with integrin?mediated adhesion.
Typical applications include scratch wound healing and Transwell migration/invasion assays to quantify motility changes, cell?spreading and adhesion assays to evaluate substrate attachment, and Western blotting for total and phosphorylated EphA2, ERK, and Akt to monitor signaling alterations. Immunofluorescence staining of F?actin and focal adhesion markers reveals cytoskeletal effects, while endothelial tube formation assays can probe paracrine angiogenic potential. The polyclonal format is well?suited for high?content screening and long?term live?cell imaging. For detailed technical support, researchers are encouraged to contact Ascent Research.
